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Abstract
Homozygotes for homocystinuria due to cystathionine synthase (CS) deficiency accumulate homocysteine and methionine in their 
blood and tissues. High-dose pyridoxin, folic acid, vitamin B12, or betaine are therapeutical options to lower the elevated homocysteine 
concentration. These compounds stimulate the transsulfuration or remethylation of homocysteine. Despite such treatment, elevated blood 
homocysteine concentrations may persist in many homocystinurics. Therefore, it is warranted to study alternative regimen to reduce the 
blood homocysteine concentration in homocystinurics. Apart from entering the transsulfuration pathway, methionine can be catabolized 
via the transamination pathway, by conversion into 4-methylthio-2-oxobutyrate (MTOB), followed by oxidative decarboxylation of 
MTOB to 3-methylthiopropionate. Thiamine pyrophosphate, the active form of thiamine, is a cofactor of the supposed rate-limiting 
oxidative decarboxylation in the transamination of methionine. The effect of thiamine administered in 2 or 3 daily doses of 25 mg orally, 
was studied in nine homozygote CS deficient patients. Methionine levels decreased in 6 out of 9 patients. In 8 out of 9 patients, however, 
the levels of plasma homocysteine remained virtually unchanged, as did the serum transamination metabolites in alt patients. We conclude 
that vitamin B 1 cannot be used as an additional homocysteine-lowering treatment in most homozygotes for homocystinuria.
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1. Introduction
Patients with classic homocystinuria due to cystathion­
ine synthase (CS) deficiency accumulate homocysteine and
in their blood and tissues. The disease is 
clinically characterized by arteriosclerosis, thromboem­
bolism, eye-lens luxation, marfanoid features, osteoporo­
sis, and mental retardation. Therapy is based on reduction 
of the hyperhomocysteinemia by stimulation of residual 
CS activity by high levels of the cofactor pyridoxal-5'- 
phosphate [1]. About 60% of these patients respond to 
pyridoxine. In poor or non-pyridoxine responsive patients, 
treatment can be extended with folic acid, vitamin B 12 or 
betaine supplementation, which enhances the homo­
cysteine remethylation (Fig. 1) [1]. As an ultimative op-
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tion, dietary methionine restriction may be mandatory to 
reduce the blood homocysteine concentration. Despite this 
variety of therapeutical options, severely elevated homo­
cysteine concentrations may persist in 
homocystinuria [2,3]. It is wart
for
additional possibilities to reduce the blood homocysteine 
concentration in homocystinurics.
Apart from entering the transsulfuration pathway, me­
thionine can also be degraded via the transamination path­
way by conversion into 4 -methylthio-2 ~oxobutyrate 
(MTOB), followed by oxidative decarboxylation of MTOB 
to 3-methylthiopropionate (Fig. I) [4]. In the latter reaction 
thiamine pyrophosphate, the active form of thiamine, is a
cofactor.
We previously demonstrated in an in vitro study that 
thiamine pyrophosphate stimulates the degradation of me­
thionine via the transamination pathway in rat liver ho-
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mogenates [5], The same result was obtained in human cysteine-lowering treatment which was also twice daily,
liver homogenates (Blom; unpublished results). In this Patients 3 and 4 are brothers, as well as patients 6 and 7
study, the methionine and homocysteine-lowering effect of (Table 1). 
thiamine (vitamin B l) was tested in nine homozygote CS
deficient patients. 2.2. Methionine and homocysteine assay techniques
2. Materials and methods
2.1. Homozygotes fo r  homocystinuria due to CS deficiency
The criteria for selection of homozygotes for homo­
cystinuria to enter this study were: regularly visiting our 
hospital, known with good compliance to their homo­
cysteine-lowering treatment, prolonged elevated 
homocysteine levels in blood despite homocysteine- 
lowering treatment for at least 2  yr, and at least 14 yr of 
age. Homozygosity for homocystinuria in nine patients 
was proven by hypermethioninemia, severe hyperhomocys- 
teinemia as well as a near to absent CS activity in cultured 
skin fibroblasts [3]. None of them were on a regimen of 
methionine restriction, except one (patient number 9; Table 
1). In addition to their conventional homocysteine-lowering 
treatment, six patients received 25 mg of thiamine hydro­
chloride for 6  weeks three times daily and three patients 
twice daily (Table 1: patient number 2 , 6  and 7). The latter 
three patients received only in total 50 mg thiamine hydro­
chloride conforming with their conventional homo-
Fasting EDTA venous blood samples were centrifuged 
immediately after puncture and stored at — 20°C until 
analysis. Methionine concentrations were determined on a 
LC 2000  amino acid analyser (Biotronik Wissenschaftliche 
Geräte, Munich, Germany) [6 ]. The total homocysteine 
concentrations (free plus protein-bound) were measured by 
a technique based on high-performance liquid chromatog­
raphy (HPLC) and fluorescent detection [7].
2.3. Transamination metabolites assay techniques
The degradation of methionine via the transamination 
pathway before and after treatment was studied by quan­
tification in serum by the sum of the transamination 
metabolites 4-methylthio-2-oxobutyrate and the mixed 
disulfides of methanethiol (R-S-S-CH3). The blood con­
centrations of these metabolites are low and near the 
detection limit, and because of reasons of accuracy, we 
prefer to measure the total sum of these transamination 
metabolites. This technique is based on gas chromatogra­
phy (Packard type 429; Packard-Becker, Delft, the Nether­
lands), supplied with a sulfur-specific flame-photometric
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Fig. 1. M etabolism  of methionine.
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Table I
The fasting blood concentrations of total homocysteine, methionine, thiamine (vitamin B l) and transamination metabolites in nine cystathionine s 
deficient patients before (-B1) and after ( - f  B l) six weeks of thiamine treatment
Patient Homoeysleine 
( /¿m ol/1)
Methionine 
( /u.mol/1)
Thiamine 
n m ol/1
Transamination 
( /xtnol/1)
Therapy
-  B l +  B1 -  Bl +  B1 -  Bl + B1 - B l  +B1
I. 143 48 98 30 98 170 0.3 0.3 750B6, B12
i  im* t 46 49 43 42 96 130 0.3 0.3 400B6, FA, B12
3. 81 82 291 123 1 10 190 0.6 0.3 750B6, FA, betaine
4. 82 79 94 54 120 210 bd bd 750B6, FA, betaine
5. 58 56 161 58 100 210 0.3 0.3 750B6, FA, betaine
6. 113 101 222 93 n p Up 0.4 0.2 500B6, FA, betaine
7. 82 120 139 188 np 210 bd bd 500B6, FA, betaine
8. 85 103 57 72 110 np 0.3 0.3 750B6, FA, B12, betaine
9. 128 109 643 490 230 330 1.0 0,7 250B6, FA, betaine, MPR
mean ±  SD 91 ±  25 83 ±  22 194 ±  127 128 ±  94 123 ±  30 207 ±  38
normal 5 to 18 16 to 47 47 to 142 bd to 1.2
Vitamin B6 (B6) was given in a daily dose in mg as indicated; folic acid (FA) was given in a daily dose of 5 mg; vitamin B12 (B 12) was given in a two 
monthly dose of 1 mg intramuscularly; betaine was given in a daily dose of 6 g; methionine poor regimen (MPR); np, not performed; bd, below level of
töüfjan
detector (Packard, model 906) [8,9], Details of the transam­
ination metabolites measurement have been reported previ­
ously [ 10].
2.4. Vitamin B l measurements
Total thiamine concentrations were determined by a 
modified procedure of the reversed-phase ion-pair HPLC 
technique described by Wielders and Mink [11]. Whole 
blood specimens are deproteinized with perchloric acid, 
followed by acid phosphatase hydrolysis of thiamine tri-, 
di- and monophosphate to thiamine, and
derivatisation of total with K,Fe(CN)f. to
thiochrome which is quantified fluorimetrically at excita­
tion and emission wave lengths of 364 nm and 462 run, 
respectively. Due to preparation steps prior to HPLC, total
analysis time of a blood s takes approx. 2 0  h 
the HPLC run itself, requires less than 10 min. The 
limit of detection of the technique is 2 .3  nmol thiamine/ 1  
and excellent linear standard dose-responses is obtained up 
to 400 nmol/1. At mean concentrations of 123 nmol/1, the 
precision of the technique revealed intra-assay and inter- 
assay coefficients of variation of 4.8% (9 assay runs) 
6 .8 % (1 0 0  consecutive assay runs), res
2.5. Statistical analysis
as mean ±  SD. F two u
Wilcoxon rank sum test was used in assessing statistical 
significance.
was 9.0 ±  2.4 yr (range 5 to 17 yr). The mean ±  SD body 
weight was 72.3 ±  10.6 kg (range 52.5 to 88.0 kg) and the 
mean ±  SD mg thiamine dosage per kg body wt. for the 
patients was 0.90 ±  0.25 mg thiamine supplementation per 
kg body weight (range 0.48 to 1.43).
The vitamin Bl plasma concentration in the homozy­
gotes for homocystinuria increased from 123 ±  30 (mean 
±  SD) nmol/1 (n — 7) before thiamine treatment to 207 ± 
38 nmol/1 (n =  7) after six weeks of thiamine treatment
1). The fasting blood concentration
from 194 ± 127  /xrnol/1 (mean ± SD)
thiamine treatment to 128 ± 9 4  iim ol/l after thiamine
% ( m u 9) ( P < 0.06). The mean fasting plasma
homocysteine concentrations not
m m ol/I
vs. 83 ±  22 /¿mol/1. Only one out of 
treated patients showed a considerable of the
concentration simultaneously with a major 
decrease of the methionine level (Table 1, patient number 
1). Currently, this patient continues the vitamin Bl supple-
3 yr basal total
mi nation is now as
of transamination
concentration at 
low as 34 ¡jlmol/1,
metabolites after thiamine did not increase in 
In fact, these levels remained low or undetectable in six
Pti
pi 
(Ti
Ï
1). Even in
i n
with a decrease of the
; concentration since the start with thiamine
the level of the transamination metabo-
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mia due to methionine adenosyl transferase (MAT) defi- lites of methionine were not elevated during thiamine
ciency do degrade quantitative amounts of methionine via administration. But, the levels of these metabolites may
the transamination pathway [12,16], whereas patients with 
hypermethioninemia due to cystathionine synthase (CS) 
deficiency do not, despite elevated methionine levels [6 ]. 
The functional impairment of methionine transamination 
may be due to the different biochemical level of the 
blockade in the methionine metabolism or due to the 
treatment of CS deficient patients by pharmacological 
amounts of vitamins, in particulary pyridoxine [6]. The 
present study was performed because of the theoretical 
possibility to lower homocysteine concentrations by en­
hancement of methionine degradation via the transamina-
have remained unchanged despite an increased methionine 
degradation through the transamination pathway. Studies 
using stable isotopes of methionine could clarify this mat­
ter.
In conclusion, orally administered thiamine lowered the 
homocysteine level in only one out of the nine homo 
cystinuric patients studied despite the reduction of the 
methionine concentration in most patients. Therefore, vita­
min B 1 appears to be only a minor alternative option for 
homocysteine-lowering treatment next to vitamin B6 , B12, 
folic acid, and betaine in homozygotes for homocystinuria.
tion pathway in CS deficient patients.
Previous in vitro studies with rats [5] and human ho-
mogenates [Blom H, unpublished data] have shown that 
thiamine pyrophosphate stimulated the methionine degra­
dation via the transamination pathway 2.5 fold. This active 
form of thiamine is a cofactor of the branched-chain
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2 -oxo-acid dehydrogenase complex which catalyses the
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